SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Array Biopharma, Inc
An SI Board Since March 2005
Posts SubjectMarks Bans Symbol
321 29 0 ARRY
Emcee:  keokalani'nui Type:  Moderated
Introduction Market Data Compact
Welcome. Please contribute.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
321Some Argue for PD-1 inhibitor longevity of action over BRAF/MEK but: Three Year GregorioAllegri-1/14/2017
320There is also competition in BRAF positive melanoma from immunotherapy MABs, speGregorioAllegri-1/14/2017
319Comparisons: median progress free survival, BRAF positive, in months. ARRY: binGregorioAllegri11/14/2017
318New trial scheduled to launch, LY2606368......... clinicaltrials.gov Results oscaram(o)uche-8/21/2015
317When I look at the chart, I see what must be a dream situation for those who trascaram(o)uche-7/28/2015
316University of Colorado Cancer Center and Loxo Oncology Announce Publication Thatscaram(o)uche-7/28/2015
315 BiotechGH@BiotechGH · 8m8 minutes ago $LOXO AACR: loxo101 ph1 very safe scaram(o)uche-4/21/2015
314old language... we'll need to do a separate deal with the company that getscaram(o)uche-1/23/2015
313[X] #ArrayBiopharma$ARRY up 25.9% will acquire the worldwide rights to encorafSI Ron (Crazy Music Man)-1/23/2015
312Wow. nice to wake up to this morning. took 1/2 my chips off the table here @ $mopgcw-1/23/2015
311Who would like to moderate this board?SI Ron (Crazy Music Man)-1/23/2015
310Big step for ARRY, finance.yahoo.comMiljenko Zuanic-1/23/2015
309More of the same, this time trametinib rather than selumetinib....... Clin Cancscaram(o)uche-1/16/2015
308I am not sure they will be able to make 162 commercial success, even if trials aMiljenko Zuanic-1/15/2015
307I didn't hear any details, just 2015. Maybe I missed it. Unbelievably lousscaram(o)uche21/15/2015
306Ya, Astra is not in a “hope mode” to try direct immuno-combination??? They are tMiljenko Zuanic-1/3/2015
305>> compelling reasoning << No. Period. But..... One might hope fscaram(o)uche-1/2/2015
304Hi all... Happy New Year! RE: ARRY Can anyone provide compelling reasoning (maybMiljenko Zuanic-1/2/2015
303Well, the knee-jerk was up, not down. Solid deal. Probably as good as best expscaram(o)uche-12/3/2014
302biz.yahoo.comtom pope-12/3/2014
301Yeah, maybe. Add that Feuerstein would chip in with "yeahrightsure, this tiscaram(o)uche-9/30/2014
300Might be worth going over the partnership agreement. Not invested and currentlytuck-8/21/2014
299We'll need to see the data. Tafinlar/Mekinist compared to Taf alone, the ASscaram(o)uche-8/1/2014
298Does this change your analysis any? combi-v OS benefit Sure didn't help thtuck-7/18/2014
297>> Meanwhile, we get no update on the cdk4/6 combo trial. << Out noscaram(o)uche-6/2/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News